First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC
OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.
Related Articles
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT])…
Program Guide – ASCO Meeting Program Guide
Jonathan Strosberg H. Lee Moffitt Cancer Center and Research Institute Jonathan Strosberg , Tyler Zemla , Susan Geyer , Michael Knopp , Spencer Behr ,…
What are Journal Content Aggregators?
Learn more about how we work with aggregators to extend the reach of our portfolio
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Diversity and Development in Hematology with Belinda Avalos, MD
You’ve successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your…
Blood Podcast | Blood | American Society of Hematology
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…
Artificial Intelligence May Expedite Prognoses in Cancer Care
In considering patients’ busy lives, AI may help reduce the number of visits required to fully stage and grade cancers.
First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer
Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.
Advancements in Breast Cancer Treatment | PBCC 2025
Register now for the 5th Annual Perspectives in Breast Cancer Care, September 12-13, 2025 and explore groundbreaking advancements in breast cancer treatment. Stay informed with…
CD22-Directed CAR-T Therapy Demonstrates Durable Remissions for Patients With Large B-Cell Lymphomas Relapsing After CD19-Directed CAR-T Therapy
Anne Marijn Kramer, MD, PhD, discusses follow-up data from a phase 1 trial showing that CD22-directed CAR-T therapy provides durable remissions and long-term survival after…
